OpGen (NASDAQ:OPGN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Thursday, Zacks.com reports. The brokerage currently has a $0.50 price objective on the medical research company’s stock. Zacks Investment Research‘s price target indicates a potential upside of 8.89% from the company’s current price.

According to Zacks, “OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland. “

OPGN has been the topic of several other reports. Alliance Global Partners started coverage on shares of OpGen in a research note on Friday, March 1st. They issued a “buy” rating and a $2.30 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $1.50 price objective on shares of OpGen in a research note on Sunday.

Shares of OPGN opened at $0.46 on Thursday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.27 and a current ratio of 1.37. The firm has a market capitalization of $4.22 million, a price-to-earnings ratio of -0.21 and a beta of 0.98. OpGen has a 1 year low of $0.36 and a 1 year high of $2.90.

OpGen (NASDAQ:OPGN) last announced its quarterly earnings data on Tuesday, February 26th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.05). The firm had revenue of $0.76 million during the quarter, compared to analyst estimates of $0.75 million. OpGen had a negative net margin of 454.23% and a negative return on equity of 313.92%. As a group, equities research analysts expect that OpGen will post -0.75 EPS for the current year.

In other news, CEO Evan/ Fa Jones acquired 417,000 shares of the company’s stock in a transaction on Thursday, March 28th. The shares were bought at an average cost of $0.60 per share, with a total value of $250,200.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 7.10% of the company’s stock.

Large investors have recently bought and sold shares of the company. Bank of New York Mellon Corp acquired a new position in shares of OpGen during the 4th quarter worth $27,000. Virtu Financial LLC acquired a new position in shares of OpGen during the 1st quarter worth $70,000. Finally, Sabby Management LLC grew its stake in shares of OpGen by 270.3% during the 1st quarter. Sabby Management LLC now owns 929,831 shares of the medical research company’s stock worth $562,000 after purchasing an additional 678,736 shares during the period. 6.98% of the stock is currently owned by institutional investors and hedge funds.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms.

Featured Story: What is the Rule of 72?

Get a free copy of the Zacks research report on OpGen (OPGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.